- About us
- Clinical Trials
- News & Publications
- Business Development
September 25, 2015
SOTIO is presenting its clinical research program at the European Society for Medical Oncology’s European Cancer Congress 2015 in Vienna (ESMO 2015). SOTIO’s exhibit can be found at booth no.1107 in ESMO Exhibition Hall B. Over the course of the ESMO Congress, SOTIO’s representatives will meet with important key opinion leaders (KOLs), researchers participating in company clinical trials and other medical and clinical experts.
The 40th annual ESMO Congress is taking place in Vienna from September 25th to 29th. More than 18,000 professionals from the fields of oncology, immunology, science and many others, are supposed to come together to share ideas and new findings with the aim of further improving treatment options in solid tumors. The ESMO Congress is one of the two biggest scientific meetings in this field, together with the ASCO Annual Meeting (the American Society of Clinical Oncology).
About SOTIO clinical development:
SOTIO’s current focus is predominantly on a new Active Cellular Immunotherapy (ACI) for prostate cancer, called DCVAC/PCa. Five “Phase II” clinical trials are currently being carried out for this treatment. SOTIO commenced the “Phase III VIABLE” global clinical trial in May 2014, in order to verify the investigational medicinal product’s safety and efficacy. The company is undertaking the clinical trial in European countries as well as in the US, with the goal of enrolling around 1,170 patients. In 2013, SOTIO also launched three “Phase II” clinical trials for a new ACI labelled DCVAC/OvCa for patients with ovarian cancer. These clinical trials are taking place in the Czech Republic, Germany and Poland. The company also initiated Phase I/II clinical trial for patients with lung cancer in the Czech Republic and Slovakia.